PD 0305970 

PD 0305970 is an orally active bacterial gyrase and topoisomerase inhibitor. PD 0305970 shows exceptional activity against gram-positive and fastidious organisms and more modest activity against gram-negative species. PD 0305970 shows low spontaneous resistance frequencies. PD 0305970 shows antibacterial efficacy in murine streptococcal sepsis and pneumococcal pneumonia models. PD 0305970 can be used for the research of bacterial infection^[1].

PD 0305970 potently inhibits growth of 1036 clinical bacterial isolates, showing exceptional activity against gram-positive and fastidious organisms and more modest activity against gram-negative species. The respective MICs (μg/mL) for PD 0305970 capable of inhibiting >90% of bacterial strains tested ranged from 0.125 to 0.5 versus staphylococci, 0.03 to 0.06 versus streptococci, 0.25 to 2 versus enterococci, and 0.25 to 0.5 versus Moraxella catarrhalis, Haemophilus influenzae, Listeria monocytogenes, Legionella pneumophila, and Neisseria spp^[1].
PD 0305970 shows low spontaneous resistance frequencies^[1].
PD 0305970 (24 h) demonstrates rapid and sustained bactericidal activity against Streptococcus pneumoniae SVI (MIC = 0.008 μg/mL) and Streptococcus pyogenes C203 (MIC = 0.008 μg/mL)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PD 0305970 (0.7-82 mg/kg; p.o.; single dose; at time of bacterial challenge) displays potent in vivo efficacy against a range of bacterial pathogens in a murine sepsis model, with PD₅₀ values ranging from 0.7 mg/kg to 82 mg/kg depending on the infecting organism^[1].
PD 0305970 (3.2-4.1 mg/kg; p.o.; once daily for 1 day, twice daily for 3 days) shows potent in vivo efficacy against both Levofloxacin (HY-B0330)-susceptible and resistant pneumococcal pneumonia in mice, with PD₅₀ values of 3.2 mg/kg and 4.1 mg/kg respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

361.41

C₁₈H₂₄FN₅O₂

351372-19-5

CC1=C2N(C3CC3)C(N(C(C2=CC(F)=C1N4C[C@](CC4)([H])[C@@H](N)C)=O)N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Huband MD, et al. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob Agents Chemother. 2007;51(4):1191-1201.